Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of canakinumab for recurrent gout flares
NL-OMON34238Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in gout, sponsored by Novartis. Primary endpoint: Long-term safety and tolerability. Started Nov 2010; status: active, not recruiting.
02
Drugs
canakinumab
03
Conditions
gout
Beyond the preview
Go deeper on NL-OMON34238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34238.